Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902382 | 0.82 | MME (0.50) | MMECTSSCTSK | |
| SCHEMBL20371160 | 0.81 | MME (0.51) | MMEPPARGPPARAMMP2MMP3 | |
| SCHEMBL18597892 | 0.79 | MME (0.48) | MMEPPARGPPARACA2CA9 | |
| SCHEMBL14890510 | 0.79 | MME (0.48) | MMEPPARGPPARACA2CA9 | |
| SCHEMBL19718236 | 0.77 | MME (0.47) | MMECA2CA9CTSSCTSK | |
| SCHEMBL19718237 | 0.77 | MME (0.47) | MMECA2CA9CTSSCTSK | |
| SCHEMBL18386377 | 0.75 | MME (0.46) | MMEMMP2MMP3CTSSCTSK | |
| SCHEMBL12735244 | 0.72 | PPARG (0.48) | MMEPPARGPPARACTSSCTSK | |
| SCHEMBL18386378 | 0.72 | MME (0.43) | MMEPPARGPPARAMMP2MMP3 | |
| SCHEMBL18626444 | 0.70 | MME (0.57) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885PPARG 4847/4885PPARA 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.